Torrent Pharmaceuticals Ratios

Torrent Pharmaceuticals Ltd Ratios

The Torrent Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Torrent Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Torrent Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Torrent Pharmaceuticals Ltd (NSE: TORNTPHARM, BSE: 500420) is currently trading at ₹4078, with a market capitalization of ₹1378.79B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Torrent Pharmaceuticals Ltd remains a key stock for fundamental analysis using Torrent Pharmaceuticals Ltd Ratios.

Torrent Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Torrent Pharmaceuticals Ltd P/E ratio currently stands at 57.28, making it one of the most tracked metrics in Torrent Pharmaceuticals Ltd Ratios.

Historically, the Torrent Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 57.28
• 2023: 53.15
• 2022: 41.78
• 2021: 60.89
• 2020: 34.35

The rising Torrent Pharmaceuticals Ltd P/E ratio indicates increasing investor confidence and premium valuation.

Price to Book Ratio (P/B)

The Torrent Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 14.42.

Historical P/B trend:

• 2024: 14.42
• 2023: 12.84
• 2022: 8.39
• 2021: 7.95

Torrent Pharmaceuticals Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Torrent Pharmaceuticals Ltd P/S ratio currently stands at 9.64, an important part of Torrent Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 9.64
• 2023: 8.30
• 2022: 5.46
• 2021: 5.58

The rising Torrent Pharmaceuticals Ltd P/S ratio indicates improved revenue valuation by investors.

Torrent Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Torrent Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 46.72.

Historical Torrent Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 46.72
• 2023: 30.27
• 2022: 25.04
• 2021: 30.48
• 2020: 25.99

The rising Torrent Pharmaceuticals Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Torrent Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Torrent Pharmaceuticals Ltd EV currently stands at ₹1120B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 1120B
• 2023: 910.77B
• 2022: 566.72B
• 2021: 508.02B

Torrent Pharmaceuticals Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Torrent Pharmaceuticals Ltd EV/EBITDA ratio is currently 30.73, a key metric in Torrent Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 30.73
• 2023: 27.36
• 2022: 20.13
• 2021: 21

Higher Torrent Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Torrent Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Torrent Pharmaceuticals Ltd D/E ratio is currently 0.42, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.42
• 2023: 0.59
• 2022: 0.87
• 2021: 0.68

Torrent Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Torrent Pharmaceuticals Ltd ROE currently stands at 26.46%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 26.46
• 2023: 25.38
• 2022: 20.50
• 2021: 13.18

Torrent Pharmaceuticals Ltd demonstrates strong profitability and efficient capital utilization.

Torrent Pharmaceuticals Ltd Ratios Analysis Summary

The Torrent Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Torrent Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Torrent Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.